Page Title
Drug Development Pipeline
Burlulipase
Status
DiscontinuedTherapeutic Approach
Nutritional-GI
Burlulipase is a liquid solution developed to treat pancreatic insufficiency caused by CF. It is a bacterial lipase that has been shown to be more resistant against inactivation by gastric acid, giving the drug the potential to be more effective than existing pancreatin products derived from pigs.
Status
A phase two trial was completed in people with CF ages 12 and older. No further clinical development in CF is planned at this time.
Sponsor
This program was sponsored by Nordmark Pharmaceuticals and conducted within the Therapeutics Development Network.
Recent Changes
12/1/2014
This program is no longer being pursued by Nordmark Pharmaceuticals.

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More